Advanced Heart Failure Therapies and Cardiorenal Syndrome
Jennifer A Cowger1, Ryhm Radjef1
1Henry Ford Hospital, Advanced Heart Failure & Cardiac Transplant Program, Detroit, MI.
Insights
Managing advanced heart failure (HF) with cardiorenal syndrome (CRS) is critical. Prompt, aggressive therapy and specialist collaboration are essential to prevent irreversible kidney failure in end-stage HF patients.
Area of Science:
- Cardiology
- Nephrology
- Cardiorenal Medicine
Background:
- End-stage heart failure (HF) carries a high mortality rate, with 1-year survival as low as 25-50%.
- Kidney disease significantly impacts HF prognosis and is integrated into HF risk stratification.
- Cardiorenal syndrome (CRS) in advanced HF presents complex management challenges, often precluding advanced therapies due to kidney failure.
Purpose of the Study:
- To outline the assessment and management strategies for patients with end-stage HF and CRS.
- To emphasize the importance of early and aggressive interventions to prevent irreversible kidney damage.
- To highlight the necessity of multidisciplinary collaboration between HF specialists and nephrologists.
Main Methods:
- Review of current medical therapies for decongestion and inotropic support in advanced HF with CRS.
- Summary of temporary circulatory support devices for eligible patients not opting for hospice care.
- Discussion of collaborative care models between advanced HF and nephrology teams.
Main Results:
- Aggressive medical management focusing on decongestion and cardiac function is crucial.
- Temporary circulatory support offers an alternative for select patients.
- Close collaboration between cardiology and nephrology is vital for optimal outcomes.
Conclusions:
- Prompt, aggressive management of CRS in end-stage HF is imperative to avert irreversible kidney failure.
- A multidisciplinary approach involving HF specialists and nephrologists is essential for improving patient survival and quality of life.
- Advanced HF therapies may be limited by cardiorenal complications, underscoring the need for timely intervention.
Abstract:
Heart failure (HF) is extremely prevalent and for those with end-stage (stage D) disease, 1-year survival is only 25-50%. Several studies have captured the mortality impact of kidney disease on patients with HF, and measures of kidney function are a component of many HF risk stratification scores. The management of advanced HF complicated by cardiorenal syndrome (CRS) is challenging, and irreversible kidney failure often limits patient candidacy for advanced HF therapies, such as transplant or left ventricular assist device therapy. Thus, prompt institution of aggressive therapy is warranted in stage D HF patients with CRS to prevent irreversible kidney failure. In this chapter, we discuss the assessment and management of patients with CRS with end-stage HF. In addition to discussing medical therapy aimed at decongestion and increased cardiac inotropy, we provide a summary of temporary circulatory support devices that can be considered for those whom hospice is not desired. In all circumstances, a close collaboration between the advanced HF specialist and nephrologist is needed to achieve the best patient outcomes.
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
01:29Heart Failure II: Pathophysiology
01:17Pathophysiology of Heart Failure
01:27Heart Failure I: Introduction
01:22Heart Failure Drugs: Diuretics
01:30Heart Failure V: Medical Management